EyeSouth Partners announced that it entered into an agreement to acquire Houston Retina Associates.
Founded in 2002, Houston Retina Associates is a leading retina care practice in the greater Houston area, with seven locations and a team of six board-certified ophthalmologists specializing in the diagnosis and treatment of retinal, macular and vitreous diseases.
EyeSouth Partners, a portfolio company of Olympus Partners as of 2022, is an eye care services organization in the Southeast. EyeSouth’s affiliate network consists of 38 practices with more than 300 doctors providing medical and surgical eye care services at more than 180 locations including 20 surgery centers throughout Georgia, Texas, Louisiana, Florida, Tennessee, Ohio, Kentucky, Alabama, Illinois, North Carolina, South Carolina and New York. EyeSouth supports its affiliated practices and physician partners with strategic guidance, administrative resources, operating expertise and capital.
This transaction represents EyeSouth’s fifth affiliation in Texas and 66th affiliation nationwide, according to the press release. Terms were not disclosed.
“At Houston Retina Associates, our mission is to combine clinical excellence with compassionate care to improve quality of life for patients affected by all forms of retinal conditions,” said Dr. Lee Tran, ophthalmologist at Houston Retina Associates. “Working with EyeSouth ensures we can continue delivering the personalized care our patients trust, while supporting our continued growth, fostering innovation in eye care and positioning our practice for long-term success.”
According to data in the LevinPro HC database, this transaction represents the 456th Physician Medical Group (PMG) acquisition of 2025, and the 28th in the eye care specialty. Eye care accounts for slightly more than 6% of all PMG transactions of the year. Throughout all of 2024, there were 26 eye care deals reported and 48 in 2023.
Other active buyers in the eye care space for the year include Eye Health America (four deals), EyeSouth Partners (four deals) and ReFocus Eye Health (three deals). Private equity buyers, and their portfolio companies, account for just under 60% of eye care acquirers in 2025.
